InVivoPure pH 8.0T Dilution Buffer
Product Details
InVivoPureā¢ dilution buffers are specifically formulated and tested to satisfy the stringent requirements for in vivo applications. They are extremely low in endotoxin, have been screened for murine pathogens, tested in animal models for toxicity and are formulated with respect to buffer composition and pH to satisfy the requirements of Bio X Cellās antibodies.Specifications
| Endotoxin |
<0.5 EU/mL (<0.0005EU/Ī¼L) Endotoxin level is determined using an LAL gel clotting test |
|---|---|
| Sterility | 0.2 Ī¼M filtered |
| Murine Pathogen Tests |
Mouse Norovirus: Negative Mouse Parvovirus: Negative Mouse Minute Virus: Negative Mouse Hepatitis Virus: Negative Reovirus Screen: Negative Lymphocytic Choriomeningitis virus: Negative Lactate Dehydrogenase-Elevating Virus: Negative Mouse Rotavirus: Negative Theilerās Murine Encephalomyelitis: Negative Ectromelia/Mousepox Virus: Negative Hantavirus: Negative Polyoma Virus: Negative Mouse Adenovirus: Negative Sendai Virus: Negative Mycoplasma Pulmonis: Negative Pneumonia Virus of Mice: Negative Mouse Cytomegalovirus: Negative K Virus: Negative |
| Toxicity Test Results | Nontoxic and nonantigenic in animal models |
| Concentration | 1X |
| Volume | 50 ml |
| Composition |
35 mM Na2HPO4 1.7 mM NaH2PO4 136 mM NaCl 0.01% TWEENĀ® 80 This buffer does not contain calcium, magnesium, phenol red, or preservatives such as azide. Keep contents sterile. Open only in a biological safety cabinet. |
| Storage | 4Ā°C |
- Cardiovascular biology,
- Immunology and Microbiology
Programming Multifaceted Pulmonary T Cell Immunity by Combination Adjuvants.
In Cell Reports Medicine on 22 September 2020 by Marinaik, C. B., Kingstad-Bakke, B., et al.
PubMed
Induction of protective mucosal TĀ cell memory remains a formidable challenge to vaccinologists. Using a combination adjuvant strategy that elicits potent CD8 and CD4 TĀ cell responses, we define the tenets of vaccine-induced pulmonary TĀ cell immunity. An acrylic-acid-based adjuvant (ADJ), in combination with Toll-like receptor (TLR) agonists glucopyranosyl lipid adjuvant (GLA) or CpG, promotes mucosal imprinting but engages distinct transcription programs to drive different degrees of terminal differentiation and disparate polarization of TH1/TC1/TH17/TC17 effector/memory TĀ cells. Combination of ADJ with GLA, but not CpG, dampens TĀ cell receptor (TCR) signaling, mitigates terminal differentiation of effectors, and enhances the development of CD4 and CD8 TRM cells that protect against H1N1 and H5N1 influenza viruses. Mechanistically, vaccine-elicited CD4 TĀ cells play a vital role in optimal programming of CD8 TRM and viral control. Taken together, these findings provide further insights into vaccine-induced multifaceted mucosal TĀ cell immunity with implications in the development of vaccines against respiratorypathogens, including influenza virus and SARS-CoV-2. Ā© 2020 The Author(s).